AstraZeneca stated in March it was aiming to ship 100 million doses in whole to the union within the first half of the yr, only a third of what was anticipated.
“This motion is because of the steady breach of the phrases of the contract and to the shortage of a dependable technique by the corporate to make sure the well timed provide of vaccines within the present circumstances,” Stefan De Keersmaecker, a spokesperson for the European Fee, stated Monday.
The European Fee filed its lawsuit in Brussels on Friday, in keeping with De Keersmaecker. An preliminary listening to will happen on Wednesday, he added. The bloc stated final week it will not train its choice to buy the 100 million further doses.
AstraZeneca in an announcement denied breaching its contract and stated that it “regrets” the European Fee’s choice to launch authorized motion.
“Following an unprecedented yr of scientific discovery, very advanced negotiations, and manufacturing challenges, our firm is about to ship nearly 50 [million] doses to European nations by the top of April, in step with our forecast,” it stated.
“AstraZeneca has absolutely complied with the Advance Buy Settlement with the European Fee and can strongly defend itself in court docket. We imagine any litigation is with out advantage and we welcome this chance to resolve this dispute as quickly as doable,” it added.
The lawsuit may mark the beginning of a prolonged court docket battle.
However European Fee officers had beforehand stated they believed the corporate was performing towards the spirit of the contract, pointing to AstraZeneca’s profitable delivering to the UK whereas failing to satisfy its targets for the bloc.
“What issues to us on this case, is that we need to ensure that there’s a speedy supply of a enough variety of doses that European residents are entitled to, and which have been promised on the premise of the contract,” stated De Keersmaecker, including all 27 nations supported this motion.
The lawsuit is the most recent in a string of issues for AstraZeneca. The corporate got here beneath scrutiny over the best way it offered its medical trial knowledge in Europe within the earlier phases of the pandemic, and extra not too long ago in the USA.
Selections from drug regulators in a number of European nations to delay advising the shot for older adults, due to an absence of trial knowledge in these age teams, could have contributed to hesitancy in taking the vaccine in elements of the continent.
And reviews of a uncommon however generally deadly blood clotting situation following use of the vaccine in youthful adults, largely girls, has prompted some nations to limit its use to solely older members of their populations. Some nations, reminiscent of Denmark, have scrapped use of the vaccine altogether.
AstraZeneca will launch its first quarter monetary outcomes on Friday.
CNN’s Lindsay Isaac contributed to this report.